Dr. Richard S. Siegel

Hematology | Oncology
880 W Central Rd, 
Arlington Heights, IL 
On Staff At
880 W Central Rd, 
Arlington Heights, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Richard Siegel is a Hematologist and an Oncologist in Arlington Heights, Illinois. Dr. Siegel is rated as an Experienced provider by MediFind in the treatment of Mondor Disease. His top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Paget Disease of the Breast, and Chronic Familial Neutropenia.

His clinical research consists of co-authoring 2 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Residency
Northwestern Memorial Hospital, Internal Medicine
Specialties
Hematology
Oncology
Licenses
Internal Medicine in IL
Board Certifications
American Board Of Internal Medicine, Hematology
Fellowships
Northwestern Memorial Hospital, Hematology/Oncology
Hospital Affiliations
Northwest Community Hospital 1
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Illinois Cancer Specialists
880 W Central Rd, Arlington Heights, IL 60005

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase 2 Clinical Study of TJ004309 in Combination With Atezolizumab (TECENTRIQ®) in Patients With Advanced or Metastatic Ovarian Cancers and Selected Advanced Solid Tumors
A Phase 2 Clinical Study of TJ004309 in Combination With Atezolizumab (TECENTRIQ®) in Patients With Advanced or Metastatic Ovarian Cancers and Selected Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: December 16, 2025
Intervention Type: Drug
Study Drugs: TJ004309, Atezolizumab
Study Phase: Phase 2
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)
Enrollment Status: Active_not_recruiting
Publish Date: October 28, 2025
Intervention Type: Drug
Study Drugs: TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel
Study Phase: Phase 1
A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer
A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: April 04, 2025
Intervention Type: Drug
Study Drug: Fruquintinib
Study Phase: Phase 3
PRESERVE 1: A Phase 3 Randomized, Double-blind Trial of Trilaciclib Versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer
PRESERVE 1: A Phase 3 Randomized, Double-blind Trial of Trilaciclib Versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer
Enrollment Status: Terminated
Publish Date: November 26, 2024
Intervention Type: Drug
Study Drug: Trilaciclib
Study Phase: Phase 3
A Randomized Phase 2/3 Multi-Center Study of SM-88 in Subjects With Pancreatic Cancer Whose Disease Has Progressed or Recurred
A Randomized Phase 2/3 Multi-Center Study of SM-88 in Subjects With Pancreatic Cancer Whose Disease Has Progressed or Recurred
Enrollment Status: Terminated
Publish Date: November 06, 2024
Intervention Type: Drug
Study Drugs: SM-88, MPS (methoxsalen, phenytoin, sirolimus), Capecitabine, Gemcitabine, 5-FU
Study Phase: Phase 2/Phase 3
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: October 31, 2024
Intervention Type: Drug, Device
Study Drugs: Gemcitabine, Nab-paclitaxel
Study Phase: Phase 3
The Circulating Cell-free Genome Atlas Study
The Circulating Cell-free Genome Atlas Study
Enrollment Status: Unknown
Publish Date: September 13, 2023
A Phase III Open-label, Multicenter Trial of Avelumab (MSB0010718C) as a Third-line Treatment of Unresectable, Recurrent, or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
A Phase III Open-label, Multicenter Trial of Avelumab (MSB0010718C) as a Third-line Treatment of Unresectable, Recurrent, or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Enrollment Status: Completed
Publish Date: November 24, 2020
Intervention Type: Drug, Other
Study Phase: Phase 3
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Enrollment Status: Completed
Publish Date: October 19, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 3
View 8 Less Clinical Trials

2 Total Publications

Guidelines for Management of Urgent Symptoms in Patients with Cholangiocarcinoma and Biliary Stents or Catheters using the Modified RAND/UCLA Delphi Process.
Guidelines for Management of Urgent Symptoms in Patients with Cholangiocarcinoma and Biliary Stents or Catheters using the Modified RAND/UCLA Delphi Process.
Journal: Cancers
Published: June 10, 2020
Similar Doctors
Experienced in Mondor Disease
Dr. Mansoina Baweja
Hematology Oncology | Hematology | Oncology
Experienced in Mondor Disease
Dr. Mansoina Baweja
Hematology Oncology | Hematology | Oncology

Endeavor Health Medical Group

801 S Washington St, 
Naperville, IL 
 (22.7 miles away)
630-527-5197
Languages Spoken:
English, Hindi, Punjabi
See accepted insurances
Accepting New Patients

Mansoina Baweja is a Hematologist Oncology specialist and a Hematologist in Naperville, Illinois. Dr. Baweja is rated as a Distinguished provider by MediFind in the treatment of Mondor Disease. Her top areas of expertise are Paget Disease of the Breast, Breast Cancer, Inflammatory Breast Cancer, and Angiosarcoma. Dr. Baweja is currently accepting new patients.

Experienced in Mondor Disease
Dr. Maria I. Quejada
Hematology Oncology | Hematology | Oncology
Experienced in Mondor Disease
Dr. Maria I. Quejada
Hematology Oncology | Hematology | Oncology

Endeavor Health Medical Group

801 S Washington St, 
Naperville, IL 
 (22.7 miles away)
630-527-5197
Languages Spoken:
English, Filipino, Spanish
See accepted insurances
Accepting New Patients

Maria Quejada is a Hematologist Oncology specialist and a Hematologist in Naperville, Illinois. Dr. Quejada is rated as a Distinguished provider by MediFind in the treatment of Mondor Disease. Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Pleuropulmonary Blastoma, and Small Cell Lung Cancer (SCLC). Dr. Quejada is currently accepting new patients.

Experienced in Mondor Disease
Dr. Leela Bhupalam
Hematology Oncology | Hematology | Oncology
Experienced in Mondor Disease
Dr. Leela Bhupalam
Hematology Oncology | Hematology | Oncology

Loyola University Medical Center

2160 S 1st Ave, 
Maywood, IL 
 (16.4 miles away)
708-216-8372
Languages Spoken:
English, Hindi, Kannada
See accepted insurances
Accepting New Patients

Leela Bhupalam is a Hematologist Oncology specialist and a Hematologist in Maywood, Illinois. Dr. Bhupalam is rated as a Distinguished provider by MediFind in the treatment of Mondor Disease. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, Angiosarcoma, and Bone Marrow Aspiration. Dr. Bhupalam is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Siegel's expertise for a condition
ConditionClose
    View All 9 Distinguished Conditions
    View All 52 Advanced Conditions
    View All 109 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile